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Abstract
At diagnosis, clonal gene rearrangement probes [retino-
ic acid receptor (RAR)-·, major breakpoint cluster region
(M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-ß,
myeloid lymphoid leukemia (MLL) or cytokine genes
(GM-CSF, G-CSF, IL-3)] were detected in bone marrow
samples from 71 of 153 patients with acute myelogenous
leukemia (AML) (46%): in 41 patients with primary AML
(pAML) (58%) and in 30 patients with secondary AML
(42%). In all cases with promyelocytic leukemia (AML-
M3) RAR-· gene rearrangements were detected (n = 9).
Gene rearrangements in the Ig-JH or the TcR-ß or GM-
CSF or IL-3 or MLL gene were detected in 12, 10, 16 and
12% of the cases, respectively, whereas only few cases
showed gene rearrangements in the M-bcr (6%) or G-
CSF gene (3%). Survival of pAML patients with TcR-ß
gene rearrangements was longer and survival of pAML
patients with IL-3 or GM-CSF gene rearrangement was
shorter than in patients without those rearrangements.
No worse survival outcome was seen in patients with
rearrangements in the MLL, Ig-JH or M-bcr gene. In
remission of AML (CR), clonal gene rearrangements
were detected in 23 of 48 cases (48%) if samples were
taken once in CR, in 23 of 26 cases (88%) if samples were
taken twice in CR and in 23 of 23 cases (100%) if samples
were studied three times in CR. All cases with gene rear-
rangements at diagnosis showed the same kind of rear-
rangement at relapse of the disease (n = 12). Our data
show that (1) populations with clonal gene rearrange-
ments can be regularly detected at diagnosis, in CR and
at relapse of AML. (2) Certain gene rearrangements that
are detectable at diagnosis have a prognostic signifi-
cance for the patients’ outcome. Our results point out the
significance of gene rearrangement analyses at diagno-
sis of AML in order to identify ‘poor risk’ patients – inde-
pendently of the karyotype. Moreover, the persistence of
clonal cells in the further course of AML can be studied
by gene rearrangement analysis.
Copyright © 2000 S. Karger AG, Basel
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Introduction
AML results in accumulation of leukemic blasts
through clonal proliferation of an abnormal progenitor
cell [1]. Clonal cell populations can be identified by cyto-
genetics, polymerase chain reaction (PCR), fluorescence
in situ hybridization (FISH) or Southern blot analysis [2,
3]. Clonal bone marrow (BM) cells, rearranged in the T
cell receptor (TcR), in immunoglobulin (Ig), in growth
factor genes (GM-CSF, G-CSF, IL-3), in the major break-
point cluster region (M-bcr) or in the myeloid lymphoid
leukemia gene (MLL), can be detected in about 50% of
the cases with acute myelogenous leukemia (AML) [4–8].
Gene rearrangements of the retinoic acid receptor-·
(RAR-·) gene are typical for promyelocytic leukemia
(AML M3). Gene rearrangements can be used to study the
presence of clonal-gene-rearranged cells in the course of
the disease [9]. About 70% of patients with AML in com-
plete remission (CR) relapse within the following 2 years.
Therefore, residual leukemic cells must have survived [9,
10]. There are only few data available about the incidence
and prognostic significance of gene rearrangements in the
genes listed above [11, 12]. In this study we present data
about the incidence and prognostic significance of certain
gene rearrangements detected at diagnosis and in the
course of AML. This may contribute important data
about the biological features of AML cells as well as for
the development of treatment strategies to restore or keep
stable remissions in AML.
Materials and Methods
Patients
BM samples from 153 AML patients at diagnosis, 81 of them
with primary AML (pAML) and 72 with secondary AML (sAML)
after myelodysplasia (MDS) were studied (all samples were obtained
from patients at the University of Munich). Mean age of the patients
was 53 years, male to female ratio was 0.9:1. Moreover, 68 patients in
CR and 25 patients at relapse according to cytological and cytochem-
ical criteria were examined. The diagnosis of AML was made accord-
ing to the French-American-British (FAB) classification. All patients
had never been treated previously and entered the study at the time
of initial therapy. Patients were treated according to approved thera-
py standards of the EORTC. CR was determined to be achieved
when the BM was normocellular, containing !5% blasts, and when
neutrophil granulocytes in peripheral blood had recovered to 1,500/
Ìl and platelets to 100,000/Ìl according to the criteria of the Cancer
and Leukemia Group [13]. Relapse was diagnosed when the BM con-
tained at least 25% leukemic blasts, or when leukemic cell infiltration
occurred at any other site. As a control, BM cells obtained from 5
healthy BM donors were studied.
Cell Preparation
BM cells were obtained after informed consent by aspiration from
the posterior iliac crest and were collected in preservative-free hepa-
rin. Mononuclear cells were obtained from BM cells by Ficoll density
gradient (density 1.077, Seromed) centrifugation and were then
washed in Hanks’ balanced salt solution with NaHCO3 (Seromed).
Immunophenotyping
Immunophenotyping by flow cytometry (Cytoron Absolute, Or-
tho Diagnostic Systems) was carried out on mononuclear BM cells in
order to estimate the percentage of cells positive for a given antibody.
The following antibodies were used: myeloid markers: CD15, labeled
with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) (Sig-
ma), and CDw65 labeled with FITC (Ortho), CD13 and CD33,
labeled with FITC or PE (Becton Dickinson); T cell markers: CD2
and CD3 labeled with PerCP (Becton Dickinson); CD4 and CD5 and
CD7, labeled with FITC (Ortho), and CD8, labeled with PE (Ortho);
B cell markers: CD10 and CD22, labeled with PE (Ortho); CD19 and
CD20, labeled with PerCP (Becton Dickinson), and blast antibody:
CD34 (class III clone 581), labeled with PE (Immunotech). More-
over, blast phenotypes at diagnosis were regularly evaluated using a
combination of different leukocyte antibodies according to consen-
sus protocols [14]. In the further course of AML, the patients’ typical
antibody combinations, including CD34 antibodies in combination
with pan myeloid antibodies (e.g. CD13, CD33), pan leukocyte anti-
bodies (CD45), were used to detect and quantify positive cells. To
avoid unspecific or epitope-class-specific variations of antibody
binding, the same antibodies of the same company were always used.
Data were evaluated using a special software (Immunocount 2) from
Ortho Diagnostic Systems.
Southern Blot Analysis
At diagnosis of AML, DNA from mononuclear BM cells of
patients was studied for gene rearrangements by Southern blot analy-
sis. Gene probes used were known to detect gene rearrangements in a
great proportion of AML cases. If a gene rearrangement was detect-
able at diagnosis, the respective gene probe was used to study the
persistence or re-emergence of gene-rearranged cells in the further
course of the disease, in CR and at relapse. DNA was prepared
according to standard procedures [15]; 10 Ìg were cut by restriction
enzymes (BamHI, HindIII or BglII from Gibco BRL); the resulting
fragments were electrophoretically separated on a 0.6% agarose gel,
blotted onto nitrocellulose and hybridized to several digoxigenated
probes: a 2.5-kb Ig-JH fragment [clone H24 (J3-6)], a 0.73-kb TcR-ß
(cß1) fragment, a 2.0-kb M-bcr (5)bcr) fragment, a 0.8-kb GM-CSF
fragment, a 1.8-kb G-CSF fragment, a 1.0-kb IL-3 fragment, a 0.74-
kb MLL fragment or a 1.64-kb RAR-· fragment in cases with pro-
myelocytic leukemia [16–21]. The reaction was developed with 5-
bromo-4-chloro-3-indolylphosphate p-toluidine salt and nitroblue te-
trazolium chloride (Boehringer, Mannheim, Germany). Bands occur-
ring in addition to the germline band were interpreted as ‘clonal
bands’ due to clonal leukemic cells.
Statistics
Statistical tests (Kaplan-Meier analysis, log rank test, Mann-
Whitney U test) were performed on a personal computer with a spe-
cial software (‘Stasy’, from Pic GmbH, and NCSS 6.0.4, from Jerry
Hintze). Differences were considered as significant in cases with p !
0.05. For survival analysis, patients were evaluated at the time of BM
transplantation.
Ig-JH
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Table 1. Southern blot analysis of BM samples from patients at diagnosis of AML using a panel of different gene probes
Gene
rearrange-
ments
AML M0
p
(1)1
s
(1)
AML M1
p
(9)
s
(15)
AML M2
p
(23)
s
(19)
AML M3
p
(7)
s
(2)
AML M4
p
(21)
s
(18)
AML M5
p
(16)
s
(5)
AML M6
p
(1)
s
(0)
AML M7
p
(0)
s
(0)
n.d.
p
(3)
s
(12)
Total
p
(81)
s
(72)
/2 1/12 1/7 0/10 0/16 3/14 0/3 0/1 5/18 1/14 2/16 1/5 0/1 / / / 0/3 0/4 8/64
13%
6/49
12%
TcR-ß 0/1 0/1 0/6 0/11 5/20 1/12 1/4 0/1 2/15 1/13 0/15 0/5 0/1 / / / 0/2 1/6 8/65
12%
3/49
6%
GM-CSF / 0/1 1/7 0/13 2/14 4/14 0/4 0/1 3/13 5/17 2/15 0/1 0/1 / / / 0/1 2/11 8/55
15%
11/61
18%
IL-3 / / 0/4 1/11 1/12 1/9 0/1 0/1 2/13 1/12 3/14 0/4 0/1 / / / 0/1 2/6 6/46
13%
5/43
12%
MLL / / 2/4 0/5 0/10 0/8 0/1 0/1 1/12 1/8 3/14 0/4 / / / / 0/1 1/5 6/43
14%
2/31
6%
RAR-· / / / / 0/5 0/1 5/5 2/2 / 0/1 / / / / / / 1/1 0/1 6/11
55%
2/5
40%
M-bcr / 0/1 0/6 0/14 1/14 1/14 1/3 0/1 2/15 0/13 2/15 0/4 0/1 / / / 0/1 0/6 6/56
11%
1/53
2%
G-CSF / 0/1 0/5 0/9 0/12 1/8 0/3 0/1 1/12 0/13 1/15 0/4 0/1 / / / 0/1 0/3 2/49
4%
1/39
3%
Gene
rearrange-
ment de-
tectable
0/1
0%
1/1
100%
4/9
44%
1/15
7%
9/23
39%
11/19
58%
7/7
100%
2/2
100%
16/21
76%
9/18
50%
13/16
81%
1/5
20%
0/1
0%
/ / / 1/3
33%
6/12
50%
41/81
51%
30/72
42%
A total of 153 cases with AML were studied at diagnosis for gene rearrangements by Southern blot analysis using a panel of different probes (Ig-JH, TcR-ß,
GM-CSF, IL-3, MLL, RAR-·, M-bcr, G-CSF). Cases, divided in FAB groups, without and with gene rearrangements after hybridization with the respective gene
probes are shown.
n.d. = Not determined.
1 Number.
2 n/n = n of n cases with gene rearrangements.
Results
Results at Diagnosis of AML
Patients’ Characteristics. BM samples of 68 cases with
undifferentiated leukemia (M0: n = 2; M1: n = 24; M2: n =
42), of 9 cases with promyelocytic leukemia (M3), of 60
cases with monocytic leukemia (M4: n = 39; M5: n = 21),
1 case with megakaryocytic leukemia (M7) and 15 mor-
phologically not classified leukemias were studied.
Eighty-one patients presented with pAML, 72 with
sAML. Male to female ratio was 0.9:1. On average, the
patients were 53 years old. Mean Hb values were 9 B 2
g/dl, WBC counts 26 B 66 ! 109/l and platelet counts 73
B 72 ! 109/l. The patients presented on average with 56
B 46% BM blasts. Most of the patients (n = 135) received
standard chemotherapy according to study protocols and
achieved CR in 58% of the cases. The remaining cases
(n = 18) were treated supportively. Two-year survival of
treated patients with pAML was 46% and that of sAML
patients 17%.
Incidence of Gene Rearrangements. Southern blot anal-
ysis could be performed in 153 patients at diagnosis of
AML; gene rearrangements could be detected in 71 (46%)
of the cases (table 1). Twelve percent (14 of 113) of the
DNA samples studied showed clonal Ig-JH gene rearran-
gements with 43% (6 of 14) of them detectable in the FAB
M4 group (table 1). Ten percent (11 of 114) of the exam-
ined cases showed clonal TcR-ß gene rearrangements,
with 55% of the rearrangements being detectable in the
FAB M2 group. Sixteen percent (19 of 116) of the cases
presented with GM-CSF gene rearrangements, with most
of the cases belonging to the FAB M2 or M4 groups. IL-3
gene rearrangements were found in 12% (11 of 89) of the
cases, preferentially in cases with FAB types M4 or M5.
MLL gene rearrangements were detected in 11% (8 of 74)
of the cases, with most of the cases classified as AML M2,
RAR-· gene rearranged
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Table 2. Clinical outcome of patients studied at diagnosis of sAML or pAML who presented with or without gene rearrangements
Gene rearrangement Survival1
months
m B Û
p value
log rank
test
Months to
relapse2
m B Û
p value
log rank
test
Response to
chemotherapy3
n/n
p value
U test
26B27 (n = 3) n.s. 20B13 (n = 2) n.s. 5/7 (71%) n.s.
RAR-· gene not rearranged 21B31 (n = 6) 16B19 (n = 7) 9/10 (90%)
M-bcr gene rearranged 5B5 (n = 5) n.s. 23B19 (n = 4) n.s. 4/6 (67%) n.s.
M-bcr gene not rearranged 10B10 (n = 64) 12B12 (n = 32) 60/98 (61%)
MLL gene rearranged 10B10 (n = 4) n.s. 21B26 (n = 4) n.s. 7/9 (78%) n.s.
MLL gene not rearranged 10B12 (n = 41) 17B17 (n = 21) 39/66 (59%)
IL-3 gene rearranged 4B4 (n = 9) !0.001 5 (n = 1) !0.05 3/9 (33%) n.s.
IL-3 gene not rearranged 10B11 (n = 48) 14B14 (n = 27) 48/76 (63%)
GM-CSF gene rearranged 6B6 (n = 12) 0.06 20B24 (n = 6) n.s. 9/16 (56%) n.s.
GM-CSF gene not rearranged 10B10 (n = 64) 12B9 (n = 32) 56/92 (61%)
G-CSF gene rearranged 8B4 (n = 3) n.s. 8B4 (n = 2) n.s. 1/3 (33%) n.s.
G-CSF gene not rearranged 15B16 (n = 35) 14B14 (n = 28) 52/82 (63%)
TcR-ß gene rearranged 20B18 (n = 5) 0.06 28B28 (n = 4) 0.06 9/11 (82%) n.s.
TcR-ß gene not rearranged 9B10 (n = 68) 13B11 (n = 36) 57/95 (60%)
Ig-JH gene rearranged 16B18 (n = 9) n.s. 20B27 (n = 4) n.s. 8/11 (73%) n.s.
Ig-JH gene not rearranged 11B14 (n = 65) 15B15 (n = 39) 61/98 (62%)
Gene-rearranged cases 11B15 (n = 42) n.s. 18B18 (n = 22) n.s. 40/63 (64%) n.s.
Not-gene-rearranged cases 11B13 (n = 57) 13B12 (n = 30) 29/56 (52%)
A total of 153 cases with AML were studied at diagnosis for gene rearrangements by Southern blot analysis using a panel of different probes
(RAR-·, M-bcr, MLL, IL-3, GM-CSF, G-CSF, TcR-ß, Ig-JH). The clinical outcome of the patients (survival, time to relapse and response to
chemotherapy) depending on detectable gene rearrangements is presented.
m B Û = Mean B standard deviation; n.s. = not significant; n/n = n of n cases studied.
1 Only patients who died.
2 Only patients who achieved a CR and who relapsed.
3 Only patients who received chemotherapy.
M4 or M5. All of the 7 cases morphologically classified as
AML M3 showed RAR-· gene rearrangements. Only 6%
(7 of 109) of the cases presented with M-bcr gene rear-
rangements and only 3% (3 of 88) with G-CSF gene rear-
rangements.
Oligoclonality. Sixteen cases presented with more than
one gene rearrangement: 4 times an M-bcr and also an
Ig-JH gene rearrangement, once an M-bcr and also an IL-
3 gene rearrangement, 6 times a TcR-ß and also an Ig-JH
gene rearrangement, 3 times a TcR-ß and also a GM-CSF
gene rearrangement and twice an Ig-JH and also a GM-
CSF gene rearrangement. In 6 samples 3 different gene
rearrangements were detected at the same time at diagno-
sis: once an M-bcr and also a GM-CSF and a G-CSF gene
rearrangement, once an M-bcr and also a TcR-ß and an
IL-3 gene rearrangement, once a TcR-ß and also an Ig-JH
and a G-CSF gene rearrangement, once a TcR-ß and an
Ig-JH and an M-bcr gene rearrangement, once an Ig-JH
and an M-bcr and an GM-CSF gene rearrangement and
once a TcR-ß and an Ig-JH and IL-3 gene rearrangement
(data not shown).
Immunophenotypes of AML Cases with Gene Rear-
rangements. In cases with RAR-· gene rearrangements,
the percentage of CD34+ cells in the BM mononuclear
cells was significantly lower as compared to cases without
RAR-· gene rearrangements (7 versus 35%; p ! 0.05, data
not shown), otherwise the percentages of CD15+ BM
mononuclear cells were higher in the group with rear-
rangements (37 versus 28%, p = 0.04). Cases with MLL
gene rearrangements showed higher counts of monocytic,
CD14+ (24 versus 16%, p = 0.04) as well as higher counts
of CD15+ BM MNC (42 versus 25%, p ! 0.03) as com-
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Fig. 1. DNA samples obtained from BM
cells at diagnosis of AML were hybridized to
a TcR-ß (a) or an IL-3-gene-specific probe
(b). Survival probabilities of cases without
(1) or with (2) the respective gene rearrange-
ments are shown. a Patients without (n =
103) or with (n = 11) TcR-ß gene rearrange-
ments. b Patients without (n = 78) or with
(n = 11) IL-3 gene rearrangements.
pared to the group without MLL gene rearrangment. Per-
centages of CD34+, CD14+ or CD15+ BM mononuclear
cells were not different in the groups with or without gene
rearrangements for the M-bcr, IL-3, GM-CSF, G-CSF,
TcR-ß or Ig-JH genes (data not shown).
Prognostic Significance of Gene Rearrangements. Sta-
tistical evaluation of our data revealed that AML patients
studied at diagnosis who presented with gene rearrange-
ments in the TcR-ß gene were characterized by a favor-
able diagnosis (survival/time to progress) whereas gene
rearrangements in the IL-3 gene indicated a poor progno-
sis (table 2, fig. 1). Gene rearrangements in the GM-CSF,
MLL or Ig-JH gene were not prognostically relevant,
although a trend to a poor prognosis was seen in patients
with GM-CSF gene rearrangements (table 2). As only few
cases exhibited rearrangements in the G-CSF gene, a
meaningful log rank test could not be performed. Hema-
tological parameters, such as WBC, Hb values or platelet
counts were not different in the groups compared (data
not shown). The clinical outcome of cases with pAML or
sAML as compared to cases without gene rearrangements
did not differ (data not shown). In pAML patients with
gene rearrangements in the TcR-ß or RAR-· genes, the
differences concerning the clinical outcome of the rear-
ranged and nonrearranged group were even more evident
than in the pooled group (pAML and sAML, data not
shown). Response to chemotherapy did not differ signifi-
cantly in the groups of patients presenting with various
gene rearrangements as compared to patients without
such rearrangements (table 2).
Concordance of Gene Rearrangements and Karyotypes.
In many cases studied by Southern blot analysis, a karyo-
type was available. We detected RAR-· gene rearrange-
ments in 5 cases without a t(15;17) and MLL gene rear-
rangements in 4 cases without 11q23 aberrations (data
not shown). In all of the cases with a t(15;17), however,
RAR-· gene rearrangements were detected as well, where-
as in 18 cases with 11q aberrations, no MLL gene rear-
rangements were seen. In 4 of 9 cases with 5q aberrations
either GM-CSF or IL-3 gene rearrangements were seen,
whereas a G-CSF gene rearrangement was detected in a
case with a 7q aberration and also in 4 cases without 7q
aberrations. All of the gene rearrangements in TcR-ß (n =
6), Ig-JH (n = 7) or M-bcr genes (n = 4) studied in parallel
did not show any chromosomal aberrations at the respec-
tive gene loci (7q35 or 14q32 or 9q34; data not shown).
Our data point out that gene rearrangements in a gene
locus do not necessarily mean an aberration detectable at
the chromosomal level and vice versa. Moreover, in 23 of
43 cases (53%) studied, clonal gene rearrangements were
demonstrated although cytogenetically normal karyo-
types were described.
In summary, our results demonstrate that gene rear-
rangements in the genes studied can be regularly demon-
strated at diagnosis of AML, with some rearrangements
occurring preferentially in certain morphological sub-
types. Moreover, our results have clinical significance:
patients with gene rearrangements in the TcR-ß gene were
characterized by a favorable prognosis, whereas patients
with IL-3 or GM-CSF gene rearrangements were charac-
terized by poor outcomes.
Disappearance of the gene
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Fig. 2. a Survival probabilities of patients
who achieved a hematological remission in
the first 3 months after chemotherapy (1; n =
133) compared to those of patients without
remission (2; n = 46) are shown. b DNA
samples obtained from BM cells in the first 3
months after chemotherapy were hybridized
to the same gene probes which had shown
gene rearrangements at diagnosis of the dis-
ease. Survival probabilities of cases with
(1; n = 13) or without (2; n = 14) a molecular
response to chemotherapy are shown.
Table 3. Concordance of hematological
and molecular response in AML patients
responding or not responding to
chemotherapy
Hematological
response achieved
yes
(n = 21)
no
(n = 6)
Rearrangement after chemotherapy
yes (n = 13)
no (n = 14)
10
11
3
3
A total of 27 BM samples obtained from patients with AML could be studied in the first 3
months after chemotherapy to study the frequency of a hematological response, a molecular
response and their concordance. Cases with or without hematological and/or molecular re-
sponse are listed.
Response to Chemotherapy. Patients presenting with
gene rearrangements at diagnosis were studied again with-
in 3 months after chemotherapy in order to find out
whether a clonal response (defined as a loss of the gene
rearrangements) is associated with a better survival prob-
ability (fig. 2). Our data show that although a significant
advantage in survival probability could be demonstrated
in cases with a hematological response to chemotherapy
in the first 3 months as compared to cases without
response (p ! 0.001, fig. 2a), no differences in survival
could be demonstrated in cases with or without gene rear-
rangements (fig. 2b). Similar results were found by com-
paring progress-free survival times (data not shown).
Moreover, we could demonstrate that 10 patients
(37%) who achieved hematological remissions also re-
sponded at the molecular level (table 3). Three patients
(11%) who did not achieve hematological remissions were
‘nonresponders’ also at the molecular level. In 11 patients
(41%), however, who responded hematologically, no mo-
lecular response could be detected, which means that a
gene rearrangement could still be detected. In 3 additional
patients (11%) who did not achieve hematological remis-
sions, a molecular response could be detected which
might also mean that more than one clone is involved in
these patients.
In conclusion, our data showed a concordance between
hematological and molecular results in 13 of 27 cases
(48%). The loss of a gene rearrangement after chemother-
apy in CR had no prognostic significance.
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Fig. 3. DNA from BM cells obtained at dif-
ferent stages of AML was prepared, cut by
restriction enzymes, electrophoresed on an
agarose gel, blotted to nitrocellulose and hy-
bridized to a digoxigenated GM-CSF gene
probe. Rearranged bands (h) in addition to
the germline bands (}) are shown.
Results in CR of AML
The goal of molecular analysis in remission was to
detect persisting gene-rearranged cells and to evaluate
their clinical significance. Therefore samples obtained at
every possible time point in CR were studied. In 23 of 48
cases (48%), the same gene rearrangement known from
diagnosis could be detected again, if BM samples were
studied once in CR. A statistical comparison of the two
groups did not show any differences in hematological or
immunological parameters or in clinical outcome (data
not shown). However, the gene rearrangement could be
detected in 23 of 26 samples (88%) if BM samples were
studied twice and in 23 of 23 samples (100%) if studied
three times in the course of CR. Figure 3 shows an exam-
ple of a Southern blot analysis in the course of AML. At
diagnosis of AML, BM cells of the patient shown were
characterized by a clonal gene rearrangement of the GM-
CSF gene. The additional band disappeared in the course
of the disease while the patient responded to therapy and
became stronger again as the patient progressed to re-
lapse. 
This means that clonal-gene-rearranged cells persist in
CR of AML and can be consistently detected in the course
of the disease by Southern blot analysis.
Results at Relapse and at Progress of AML
BM samples from 25 patients could be studied at
relapse. In 12 of them, the same gene rearrangement
known from diagnosis could be detected in the following
genes: 4 times for the GM-CSF, twice for M-bcr, Ig-JH
and RAR-· genes, once for the MLL and TcR-ß genes. In
the remaining 13 cases again, as at diagnosis, no gene rear-
rangement could be detected. A statistical comparison of
cases with or without gene rearrangements at relapse did
not show any differences concerning survival or progress-
free survival times or response rates to chemotherapy
between the two groups (data not shown). No differences
could be detected when comparing hematological param-
eters (hemoglobin, white blood cells, platelets, BM/pe-
ripheral blood blasts) or percentages of immunologically
detectable granulocytes, monocytes, T/B cells, CD34+
cells, erythropoietic or megakaryopoietic cells in the two
groups (data not shown).
Eight cases presenting with gene rearrangements at
diagnosis of sAML after a phase of MDS could be studied
shortly before their progress to AML. In 3 of the 8 cases,
clonal-gene-rearranged cells could already be detected 2–
6 months before the clinical onset of AML (data not
shown).
This means that disease progression can be detected
early by Southern blot analysis and that relapse of AML is
caused by a regrowth of the same clone as at diagnosis.
Therefore, our data show that clonality analysis allows to
monitor the present status of patients with AML.
Control Experiments
DNA obtained from BM or peripheral blood samples
of patients with nonhematological diseases served as con-
trols (n = 5). Those DNA samples were regularly studied
for gene rearrangements in parallel with the gene probes
used in every experiment. No clonal gene rearrangements
were detected in the control samples. 
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Discussion
Gene Rearrangements at Diagnosis of AML
Incidence of Gene Rearrangements. AML is a stem cell
disease developing clonally, but it is heterogeneous with
respect to cell differentiation [1]. Southern blot analysis is
a suitable tool to detect clonal-gene-rearranged cell popu-
lations at diagnosis of AML. Compared to cytogenetics,
Southern blot analysis has the advantage that it is inde-
pendent of proliferation and therefore allows the detec-
tion of clonal gene rearrangements in dividing and non-
dividing cells. Moreover, the detection of a clonal marker
in cases without chromosome abnormalities is possible.
We could detect gene rearrangements in Ig-JH, TcR-ß,
GM-CSF, G-CSF or IL-3 genes in 12, 10, 16, 3 or 12% of
the cases, respectively, with 53% (23 of 43 cases) present-
ing with a normal karyotype. Gene rearrangements in a
variety of different genes, such as growth factor genes
(GM-CSF, IL-3, G-CSF), RAR-·, MLL, M-bcr, Ig-JH or
TcR-ß genes, are known to be found in a certain propor-
tion of AML cases [5–9 and own unpubl. data]. In agree-
ment with the literature, we could demonstrate that RAR-
· gene rearrangements are specific to cases with AML-M3
[22]. Therefore, Southern blot analysis contributes impor-
tant data to assure diagnosis of patients with promyelocyt-
ic leukemia, especially in those cases without cytogeneti-
cally detectable t(15;17) aberrations [2].
Concordance of Gene Rearrangements and Karyotypes
and Their Prognostic Significance. Although a tendency to
a better outcome could be demonstrated in patients pre-
senting with RAR-· gene rearrangements, it was an aston-
ishing finding that the clinical outcome of patients with-
out RAR-· gene rearrangements was not significantly
worse. This may be attributed to the low number of AML
M3 cases studied (n = 9) or to the fact that, besides the M3
FAB type (13%, 9 of 71 cases), a large proportion of
patients (20 of 71 cases, 28%) studied in this group pre-
sented AML M2, which has a favorable prognosis as well.
Therefore, the clinical outcomes of the group without and
the group with RAR-· gene rearrangements were similar.
MLL gene rearrangements could be detected in 11% of
the cases studied, with most of the rearranged cases occur-
ring in FAB groups M1, M4 and M5, as already described
[23]. Moreover, MLL gene rearrangements could be de-
tected in 4 cases, which were studied in parallel by cyto-
genetics but did not show 11q23 aberrations. This was
also observed by other authors [23].
Our data show that gene rearrangements in a gene
locus do not mean a chromosomal aberration at the
respective band and vice versa. Especially in cases with
cytogenetically undetectable or masked chromosomal
aberrations, Southern blot analysis could therefore help to
identify certain subgroups. This could be of clinical signif-
icance, notably in cases with therapeutically and prognos-
tically different outcomes, such as AML M3 cases.
Prognostic Significance of Gene Rearrangements. Sta-
tistical evaluation of our data showed that gene rear-
rangements in the TcR-ß and the RAR-· gene mean a
favorable diagnosis for patients with AML. Rearrange-
ments in the MLL, the Ig-JH or the M-bcr genes mean an
intermediate prognosis and rearrangements in the IL-3 or
GM-CSF gene mean an unfavorable or at least a tendeny
to an unfavorable prognosis. Concerning the RAR-· rear-
rangements, our data are in agreement with the literature,
according to which those rearrangements are typical for
AML M3 and mean a favorable prognosis [22]. Our data
point out that MLL gene rearrangements do not necessari-
ly mean an unfavorable prognosis, as already shown by
others [24]. An astonishing finding was that TcR-ß gene
rearrangements are associated with a favorable prognosis
for patients with pAML. This means that 7q aberrations
do not necessarily represent an unfavorable prognosis,
with prognosis depending on the gene loci involved.
Whereas other groups have shown that a rearrangement
in the Ig-JH gene detectable by PCR means a worse prog-
nosis for the patients [11], our results did not reveal any
prognostic significance for patients with Ig-JH gene rear-
rangements as compared to patients without such rear-
rangements. The differences between our data and those
of Kyoda et al. [11] could be due to the different detection
method or gene probes used or to the fact that in our
patient cohort only 34 of 113 tested cases (30%) belonged
to the prognostically favorable groups with FAB type M2
or M3, versus 21 of 35 cases (60%) in the group presented
by Kyoda et al. An IL-3 or GM-CSF gene rearrangement
means an unfavorable prognosis. This could be due to the
fact that 4 of 9 patients who could be studied in parallel by
cytogenetics also presented with solitary or complex 5q
aberrations, which means a very unfavorable prognosis
[24, 25]. Moreover, our data point out that gene loci for
the IL-3 or GM-CSF gene on locus 5q31 need not be de-
leted in case of a 5q aberration, as discussed by some
authors [26], but could be translocated or rearranged at a
molecular level. Alternatively, the rearrangements could
also have happened on the second chromosome without
the 5q aberration. The prognostic significance of a G-CSF
rearrangement could not be evaluated because of the fact
that only 3 cases presented with such gene rearrange-
ments. Due to low amounts of cells or DNA available in
some patients, DNA could not be hybridized with all gene
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probes. Samples were classified as ‘not rearranged’ if
DNA samples were tested and not rearranged with at least
one gene probe. This means that gene rearrangements
might have been overlooked. 
Immunophenotypes of AML Cases with Gene Rear-
rangements. In cases with a rearranged RAR-· gene, the
percentage of CD34+ cells was significantly lower than in
the group with a nonrearranged RAR-· gene, whereas
CD15+ cell counts were higher. Cases with MLL gene
rearrangements showed higher counts of monocytic cells
(CD14). Those data fit well with the literature demon-
strating that BM cells obtained from patients with AML-
M3 do not express CD34 but CD15 antigens and that in a
large proportion of patients, MLL gene rearrangements
occur in cases with (myelo-) monocytic AML (AML M4,
M5) [14, 27]. Moreover, our data show that studying gene
rearrangements and immunophenotypes can help learn
about biological features of proliferation and differentia-
tion in certain subtypes of AML.
Oligoclonality in AML. In 16 BM samples, more than
one gene rearrangement could be detected at diagnosis of
AML. This could indicate that one AML clone is charac-
terized by multiple clonal genetic rearrangements in these
cases. Alternatively, this could mean the coexistence of
several clones with different gene rearrangements, as
already shown by others and us [28].
Gene Rearrangements in the Course of AML
Gene Rearrangements in CR. About 70% of patients
with AML in CR relapse within the following 2 years [10].
Therefore, residual leukemic cells must have survived.
Those cells can be detected by different methods, such as
PCR, FISH or Southern blot analysis [9]. With Southern
blot analysis, we could detect clonal-gene-rearranged cells
in 46% of the cases if samples were studied once, in 88%
of the cases if studied twice and in 100% of the cases if
BM DNA was studied three times during the course of
CR. This means that clonal-gene-rearranged cells regular-
ly persist in CR, but cannot be detected at every time
point due to bad quality of BM aspirates, low amounts of
DNA or because of the limited sensitivity of 1–5% of
Southern blot analyses [29]. These facts can also be
responsible for our finding that patients with gene rear-
rangements in CR do not have a worse treatment outcome
than those who lost the rearrangements.
Our data show that Southern blot analysis is a suitable
method to study the persistence of clonal cells, especially
in cases without chromosomal aberrations, which can be
detected by PCR or FISH in a large proportion of cases [9,
30].
Gene Rearrangements on Progress of AML. We could
show that gene rearrangements detectable at relapse are of
the same kind as at diagnosis, pointing to the fact that the
same leukemic clone induces the relapse. In our patient
cohort, no favorable clinical outcome could be demon-
strated for those patients without detectable gene rear-
rangements as compared to the cases with gene rear-
rangements at relapse. This could be explained by the fact
that 3 of those rearranged 12 cases which could be studied
at relapse presented with ‘favorable gene rearrangements’
(RAR-· or TcR-ß gene) and 5 with gene rearrangements
without any prognostic significance. Moreover, our data
show that Southern blot analysis is a good method to
detect a progress of the disease early: clonal-gene-rear-
ranged cells could be detected 2–6 months before the clini-
cal onset of AML after a phase of MDS.
This means that Southern blot analysis is an efficient
method not only to ascertain a relapse, but also to detect
progress of the disease early.
Although in cases with chromosomal aberrations dis-
covered at diagnosis, residual leukemic cells can be de-
tected more easily by PCR or FISH if the appropriate
primers or probes are available [9, 30], Southern blot
analysis is also a good method to detect residual cells,
especially in cases without cytogenetic markers. There-
fore, the persistence of clonal cells can be monitored at a
molecular level and allows the detection of oligoclonal
disease [28], extramedullary relapse [31] or – in combi-
nation with immunophenotyping – the detection of
gene-rearranged, but differentiated leukemic cells [28,
31–33].
Conclusions
In conclusion, our results show that Southern blot anal-
ysis can be used to study clonality and evaluate the prog-
nostic value of gene rearrangements at diagnosis of AML.
Moreover, the persistence or re-emergence of clonal cells
in CR or at relapse can be studied. The goal of molecular
diagnosis in AML in the future should be to detect a clon-
al BM marker in every AML patient at diagnosis. The
molecular cloning of many genes involved in cancer
development could help to find new gene probes for the
characterization of leukemic disease [25]. Furthermore,
the value of the detection of residual disease in AML has
to be studied in detail: perhaps not the presence but the
amount of clonal DNA/clonal cells is predictive for re-
lapse. Moreover, analyses of samples obtained at stan-
dardized time points (e.g. shortly after induction therapy,
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after 3, 6, 9, 12 months in CR) have to be performed to
evaluate the value of Southern blot analysis for screening
of residual clonal cells in CR and to evaluate their clinical
significance.
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